我們已在上線!
進一步了解
Elevation Oncology
ELEV
ELEV
已下市
ELEV已於2025年7月22日下市。
公司簡介: Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
員工: 34
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
價格圖表採用Lightweight Charts™實作